Skip to Main Content

And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is exceedingly low-key. We plan to catch up on some reading, putter about the Pharmalot grounds, and promenade extensively with the official mascot. And what about you? Once again, the great outdoors is beckoning and the choices are plentiful — you could lace up your hiking boots, get some sand between your toes, or cruise the countryside. This may be an opportunity to plan a quiet evening watching a moving picture or two. Or you could catch up with someone special. Well, whatever you do, have a grand time. But be safe. Enjoy, and see you soon. …

Bristol Myers Squibb agreed to buy Turning Point Therapeutics, a clinical-stage precision-oncology company, for $4.1 billion to deepen its position in lung-cancer treatments, STAT writes. With the deal, Bristol Myers will add Turning Point’s lead asset, repotrectinib, a next-generation, potential best-in-class tyrosine kinase inhibitor targeting certain drivers of non-small cell lung cancer and other advanced solid tumors. Bristol Myers expects repotrectinib to win U.S. Food and Drug Administration approval in the second half of 2023 and become a new standard of care for patients with ROS1-positive, non-small cell lung cancer.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment